Multiple patients have survived substantially beyond expected median survival, including one patient who survived 28 months and several patients who remain alive with continued follow-up
SAN JOSE, Calif. , May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
ORLANDO, FL / ACCESS Newswire / May 1, 2026 / RedChip Companies will air interviews with Anixia Biosciences, Inc. (NASDAQ:ANIX) and OwlTing Group (NASDAQ:OWLS), the operating brand of OBOOK Holdings Inc.,...
Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial
ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...
ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial
SAN JOSE, Calif. , April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...